文献速递造血干细胞移植与细胞治疗

如何开展移植后环磷酰胺单倍体造血干细胞移植

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide.
PubMed 文献 · Blood · 2019-01-01

单倍体造血干细胞移植是常用替代供者方案,多数中心采用巴尔的摩组开发的高剂量移植后环磷酰胺方案。该方案严重移植物抗宿主病和非复发死亡率低,无需移植物处理或储存,获取成本低;在减强度预处理下安全性良好,75岁以下患者结局与50余岁患者相似。多项注册回顾性研究显示其疗效与HLA相合移植相当。

要点

  • 移植后环磷酰胺单倍体移植严重GVHD和非复发死亡率低。
  • 减强度预处理下75岁以下患者结局与50余岁相似。
  • 注册研究显示疗效与HLA相合移植相当。

核心结论

  • 移植后环磷酰胺单倍体移植是安全有效的替代供者平台,疗效与HLA相合移植相当。

研究设计与样本

  • 本文为单中心经验描述,结合多项注册回顾性研究证据,未报告具体样本量。

主要发现

  • 该方案严重GVHD和非复发死亡率低,无需移植物处理或储存,获取成本低。
  • 减强度预处理下75岁以下患者结局与50余岁患者相似。
  • 多项大型注册回顾性研究证实其疗效与HLA相合移植相当。

临床怎么用

  • 采用高剂量移植后环磷酰胺的T细胞充足单倍体移植平台,无需移植物处理或储存,可快速开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. McCurdy SR, Luznik L. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide. Blood. 2019. PMID: 31751485. doi:10.1182/blood.2019001323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。